Who are Phathom Pharmaceuticals, Inc.'s main suppliers?

Phathom Pharmaceuticals, Inc. (PHAT) key suppliers include: Hercules Capital, Inc., Hercules Capital, Inc., ORANY, ORANY, RedHill Biopharma Ltd. and 3 more. View the full supplier network at chainsifter.com/chain/PHAT.

Who are Phathom Pharmaceuticals, Inc.'s major customers?

Phathom Pharmaceuticals, Inc. (PHAT) key customers include: CUSTOMER, Hercules Capital, Inc., Hercules Capital, Inc., ORANY, ORANY and 5 more. View the full customer network at chainsifter.com/chain/PHAT.

What sector is Phathom Pharmaceuticals, Inc. in?

Phathom Pharmaceuticals, Inc. (PHAT) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Phathom Pharmaceuticals, Inc. Supplier List (PHAT): 8 Verified Suppliers

8Suppliers

10Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Phathom Pharmaceuticals, Inc. (PHAT) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

21Total relationships

3Distinct source URLs

4High confidence

0.750Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Phathom Pharmaceuticals, Inc. Suppliers

Ticker	Name	Confidence	Evidence
HTGC	Hercules Capital, Inc.	72%	te vonoprazan in the future. We may expend our limited resources to pursue a particular indication or formulation for vonoprazan and fail to capitalize on product candidates, indications or formulati…
HTGC	Hercules Capital, Inc.	72%	Reciprocal relationship from HTGC graph: Reciprocal relationship from PHAT graph: te vonoprazan in the future. We may expend our limited resources to pursue a particular indication or formulation for…
ORANY	ORANY	72%	tent that any disruption or cybersecurity incident were to jeopardize the confidentiality, integrity, or availability of our information systems, or result in a loss of, or damage to, our data or app…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from PHAT graph: tent that any disruption or cybersecurity incident were to jeopardize the confidentiality, integrity, or availabilit…
RDHL	RedHill Biopharma Ltd.	72%	Reciprocal relationship from RDHL graph: Reciprocal relationship from PHAT graph: ribution 53 capabilities in 2021 in advance of the planned commercialization of VOQUEZNA, VOQUEZNA TRIPLE PAK and VOQ…
RDHL	RedHill Biopharma Ltd.	72%	ribution 53 capabilities in 2021 in advance of the planned commercialization of VOQUEZNA, VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, due to approval and launch delays, we did not hire our field force…
TKPHF	Takeda Pharmaceutical Company Limited	72%	ology, product commercialization, and pharmaceutical operations. Our commercial strategy is focused on driving awareness and adoption among healthcare providers who routinely treat patients with GERD…
TKPHF	Takeda Pharmaceutical Company Limited	72%	Reciprocal relationship from TKPHF graph: Reciprocal relationship from PHAT graph: Reciprocal relationship from TKPHF graph: Reciprocal relationship from PHAT graph: ology, product commercialization,…

Phathom Pharmaceuticals, Inc. Customers

Ticker	Name	Confidence	Evidence
CUSTOMER	CUSTOMER	92%	For the three months ended March 31, 2025, three customers accounted for 76% of the product sales
HTGC	Hercules Capital, Inc.	72%	50.0 percent if such prepayment is a result of a change in control and (y) upon any refinancing by Hercules such prepayment charge shall be waived in full; and (viii) provided for a new final payment…
HTGC	Hercules Capital, Inc.	72%	Reciprocal relationship from HTGC graph: Reciprocal relationship from PHAT graph: 50.0 percent if such prepayment is a result of a change in control and (y) upon any refinancing by Hercules such prep…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from PHAT graph: rtain privacy laws such as GDPR) or confidential information, or jeopardize the confidentiality, integrity, or avail…
ORANY	ORANY	72%	rtain privacy laws such as GDPR) or confidential information, or jeopardize the confidentiality, integrity, or availability of our information systems or any information residing therein, it could re…
RDHL	RedHill Biopharma Ltd.	72%	ribution 53 capabilities in 2021 in advance of the planned commercialization of VOQUEZNA, VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, due to approval and launch delays, we did not hire our field force…
RDHL	RedHill Biopharma Ltd.	72%	Reciprocal relationship from RDHL graph: Reciprocal relationship from PHAT graph: ribution 53 capabilities in 2021 in advance of the planned commercialization of VOQUEZNA, VOQUEZNA TRIPLE PAK and VOQ…
TKPHF	Takeda Pharmaceutical Company Limited	72%	ology, product commercialization, and pharmaceutical operations. Our commercial strategy is focused on driving awareness and adoption among healthcare providers who routinely treat patients with GERD…
TKPHF	Takeda Pharmaceutical Company Limited	72%	Reciprocal relationship from TKPHF graph: Reciprocal relationship from PHAT graph: ology, product commercialization, and pharmaceutical operations. Our commercial strategy is focused on driving aware…
NQ-SAGARD-HOLDINGS	NQ-SAGARD-HOLDINGS	62%	50.0 percent if such prepayment is a result of a change in control and (y) upon any refinancing by Hercules such prepayment charge shall be waived in full; and (viii) provided for a new final payment…

Phathom Pharmaceuticals, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
PHAT-DEBT	Debt stack $164.6M	90%	Market cache reports total debt of $164.6M.
PHAT-DEBT-11764	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2019-12-31.
PHAT-DEBT-11763	Warrants outstanding: 1290000	90%	xbrl warrant detail from xbrl 2021-12-31.

Phathom Pharmaceuticals, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Phathom Pharmaceuticals, Inc..

Phathom Pharmaceuticals, Inc. Ownership

No ownership data on recordNo major institutional ownership relationships found in our database for Phathom Pharmaceuticals, Inc..

Phathom Pharmaceuticals, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
MDGL	Madrigal Pharmaceuticals, Inc.	100.00	2
OBIO	Orchestra BioMed Holdings, Inc.	100.00	2
CMPS	COMPASS Pathways plc	100.00	2
KURA	Kura Oncology, Inc.	100.00	2
RCUS	Arcus Biosciences, Inc.	100.00	2
MAZE	Maze Therapeutics, Inc.	100.00	2
IRON	Disc Medicine, Inc.	100.00	2
ALEC	Alector, Inc.	100.00	2
SVRA	Savara Inc.	100.00	2
TKPHF	Takeda Pharmaceutical Company Limited	100.00	1	['customer', 'supplier']
PHGE	BiomX Inc.	100.00	2
SGHT	Sight Sciences, Inc.	100.00	2
RDHL	RedHill Biopharma Ltd.	100.00	1	['customer', 'supplier']
REPL	Replimune Group, Inc.	100.00	2
BCYC	Bicycle Therapeutics plc	100.00	2
DYN	Dyne Therapeutics, Inc.	100.00	2
ORANY	ORANGE	100.00	1	['customer', 'supplier']
ALT	Altimmune, Inc.	100.00	2
ENGN	enGene Therapeutics Inc.	100.00	2
VRDN	Viridian Therapeutics, Inc.	100.00	2

Phathom Pharmaceuticals, Inc. Supply Chain